Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma

Sponsor
Peking University Cancer Hospital & Institute
Study ID
NCT05321316
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Accepted

Interventions

  • 18F-FDG — DRUG
    All study participants will undergo one 18F-FDG PET/CT scan.

Study Details

To evaluate the ability of \[68Ga\]N188 to detect nectin-4 overexpression in patients with urothelial carcinoma, especially in patients with recurrent or advanced bladder cancer.

Key Dates

First listed
Apr 11, 2022
Start date
May 31, 2026
Status verified
Mar 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: 68Ga-N188
    Imaging cohort All study participants will be allocated to this arm (single-arm study). Study participants will undergo 68Ga-N188 PET/CT scan.

Primary Outcome Measure

Standardized uptake value（SUV） [ Time Frame: 2 years ]

Central Contacts

Find similar trials

Nationwide
Bladder cancer trialsOncology trialsUrology trials

Related Studies